CD3

Beyond's analysis on CD3

• 2026-08-25 — Antengene secures Australian regulatory clearance to launch a first-in-human Phase I trial of its CD19xCD3 T-cell engager ATG-201 for B-cell autoimmune disorders

Recent news mentioning CD3

• 2026-09-10 — Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
• 2026-08-25 — Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

Appears alongside

• CD19
• TCE

Browse the full archive →